LCP
KITE

Lamond Capital Partners’s Kite Pharma, Inc. KITE Stock Holding History

Lamond Capital Partners’s Portfolio KITE Stock Details KITE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-105,498
Closed -$6.64M – 16
2015
Q2 		$6.43M Buy
105,498
+1,248
+1% +$71.2K 6.53% 8
2015
Q1 		$6.01M Sell
104,250
-261,650
-72% -$17.5M 6.57% 7
2014
Q4 		$21.1M Buy
+365,900
New +$15.4M 13.82% 2

Other funds holding KITE

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Lamond Capital Partners's KITE Position: Q3 2015 in Review

Lamond Capital Partners sold out of Kite Pharma, Inc. (KITE) in Q3 2015, closing a stake of 105,498 shares — an estimated $6.64M sold.

Lamond Capital Partners first reported a position in KITE in Q4 2014 and held it in 3 quarters. The position peaked at $21.1M in Q4 2014. 155 funds tracked by Wall St. Rank hold KITE as of Q3 2015.

  • Lamond Capital Partners reported no remaining Kite Pharma, Inc. position as of Q3 2015 after selling out during the quarter.
  • Lamond Capital Partners sold 105,498 Kite Pharma, Inc. shares in Q3 2015, an estimated $6.64M.
  • Lamond Capital Partners first reported a position in Kite Pharma, Inc. in Q4 2014 and held it in 3 quarters.
  • Lamond Capital Partners's Kite Pharma, Inc. position peaked at $21.1M in Q4 2014.
  • 155 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q3 2015.

Based on Lamond Capital Partners's 13F filing for Q3 2015, filed 9 Nov 2015.